260 related articles for article (PubMed ID: 21116326)
1. Proteasome inhibition and its therapeutic potential in multiple myeloma.
Chari A; Mazumder A; Jagannath S
Biologics; 2010 Sep; 4():273-87. PubMed ID: 21116326
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Richardson PG; Hideshima T; Anderson KC
Cancer Control; 2003; 10(5):361-9. PubMed ID: 14581890
[TBL] [Abstract][Full Text] [Related]
4. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Panobinostat for the Treatment of Multiple Myeloma.
Eleutherakis-Papaiakovou E; Kanellias N; Kastritis E; Gavriatopoulou M; Terpos E; Dimopoulos MA
J Oncol; 2020; 2020():7131802. PubMed ID: 32411240
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition: novel therapy for multiple myeloma.
Kaufman JL; Lonial S
Onkologie; 2006 Apr; 29(4):162-8. PubMed ID: 16601373
[TBL] [Abstract][Full Text] [Related]
7. Nonselective proteasome inhibitors in multiple myeloma and future perspectives.
Gavriatopoulou M; Malandrakis P; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Opin Pharmacother; 2022 Feb; 23(3):335-347. PubMed ID: 34761710
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
Paoluzzi L; O'Connor OA
BioDrugs; 2006; 20(1):13-23. PubMed ID: 16573348
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
[TBL] [Abstract][Full Text] [Related]
11. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
12. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
13. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Citrin R; Foster JB; Teachey DT
Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
[TBL] [Abstract][Full Text] [Related]
14. A Landmark Paper That Introduced Proteasome Inhibition in Myeloma.
Devasia AJ; Lancman G; Stewart AK
Cancer Res; 2023 Oct; 83(19):3174-3175. PubMed ID: 37779426
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors in the treatment of multiple myeloma.
McBride A; Ryan PY
Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
[TBL] [Abstract][Full Text] [Related]
16. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
[TBL] [Abstract][Full Text] [Related]
17. Targeting the ubiquitin-proteasome pathway in cancer therapy.
Ishii Y; Waxman S; Germain D
Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
[TBL] [Abstract][Full Text] [Related]
18. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
Reece D; Imrie K; Stevens A; Smith CA;
Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
[TBL] [Abstract][Full Text] [Related]
20. Targeting the UPS as therapy in multiple myeloma.
Chauhan D; Bianchi G; Anderson KC
BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S1. PubMed ID: 19007431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]